Literature DB >> 23453716

Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer.

S L Sudenga1, S Shrestha.   

Abstract

Persistent infection with human papillomavirus (HPV) causes essentially all precancerous cervical lesions and cervical cancer in females and thus is an important intermediate phenotype to cervical cancer. A majority of infected individuals naturally clear HPV viral infection, but the virus persists in a subset of infected hosts and the mechanism for this differential outcome is not well described. Most of the epidemiological studies have been cross-sectional in nature, and even with longitudinal studies, the definition of HPV persistence or clearance has not been well defined. There is no consensus on the correct time interval between HPV DNA tests, or how to utilize HPV persistence information in clinical management because there is no treatment for HPV. While most studies are performed with the endpoint of cancer, the intermediate phenotype has been overlooked. Epidemiological studies of HPV persistence suffer with several challenges in definitions, study designs, and analyses that undermine its importance in identifying and understanding the interactions between the viral and host genomes in the process of HPV infection pathogenesis. We have evaluated the current status of HPV persistence and provide perspectives on how the field would benefit from a research focus on intermediate phenotype in epidemiological studies.
Copyright © 2013 International Society for Infectious Diseases. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23453716      PMCID: PMC3602330          DOI: 10.1016/j.ijid.2012.12.027

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  32 in total

1.  Concurrent and sequential acquisition of different genital human papillomavirus types.

Authors:  K K Thomas; J P Hughes; J M Kuypers; N B Kiviat; S K Lee; D E Adam; L A Koutsky
Journal:  J Infect Dis       Date:  2000-09-05       Impact factor: 5.226

Review 2.  Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia.

Authors:  Mark H Schiffman; Philip Castle
Journal:  J Natl Cancer Inst       Date:  2003-03-19       Impact factor: 13.506

3.  Detection of genital human papillomavirus and associated cytological abnormalities among college women.

Authors:  K L Kotloff; S S Wasserman; K Russ; S Shapiro; R Daniel; W Brown; A Frost; S O Tabara; K Shah
Journal:  Sex Transm Dis       Date:  1998-05       Impact factor: 2.830

Review 4.  Natural history of cervical intraepithelial neoplasia: a critical review.

Authors:  A G Ostör
Journal:  Int J Gynecol Pathol       Date:  1993-04       Impact factor: 2.762

5.  Natural history of cervicovaginal papillomavirus infection in young women.

Authors:  G Y Ho; R Bierman; L Beardsley; C J Chang; R D Burk
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

6.  The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women.

Authors:  A B Moscicki; S Shiboski; J Broering; K Powell; L Clayton; N Jay; T M Darragh; R Brescia; S Kanowitz; S B Miller; J Stone; E Hanson; J Palefsky
Journal:  J Pediatr       Date:  1998-02       Impact factor: 4.406

7.  Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study.

Authors:  Martyn Plummer; Rolando Herrero; Silvia Franceschi; Chris J L M Meijer; Peter Snijders; F Xavier Bosch; Silvia de Sanjosé; Nubia Muñoz
Journal:  Cancer Causes Control       Date:  2003-11       Impact factor: 2.506

8.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 9.  Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis.

Authors:  Anne F Rositch; Jill Koshiol; Michael G Hudgens; Hilda Razzaghi; Danielle M Backes; Jeanne M Pimenta; Eduardo L Franco; Charles Poole; Jennifer S Smith
Journal:  Int J Cancer       Date:  2012-10-11       Impact factor: 7.396

Review 10.  Findings to date from the ASCUS-LSIL Triage Study (ALTS).

Authors:  Mark Schiffman; Diane Solomon
Journal:  Arch Pathol Lab Med       Date:  2003-08       Impact factor: 5.534

View more
  17 in total

1.  Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial.

Authors:  Staci L Sudenga; B Nelson Torres; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim Van der Loeff; Louvina E Van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano
Journal:  J Infect       Date:  2015-10-19       Impact factor: 6.072

2.  TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.

Authors:  Zheng Hu; Wencheng Ding; Da Zhu; Lan Yu; Xiaohui Jiang; Xiaoli Wang; Changlin Zhang; Liming Wang; Teng Ji; Dan Liu; Dan He; Xi Xia; Tao Zhu; Juncheng Wei; Peng Wu; Changyu Wang; Ling Xi; Qinglei Gao; Gang Chen; Rong Liu; Kezhen Li; Shuang Li; Shixuan Wang; Jianfeng Zhou; Ding Ma; Hui Wang
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

Review 3.  Vaginal microbiomes and ovarian cancer: a review.

Authors:  Jinyun Xu; Jing-Jie Peng; Wenqing Yang; Kun Fu; Yu Zhang
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

4.  Functional variants in CYP1A1 and GSTM1 are associated with clearance of cervical HPV infection.

Authors:  Staci L Sudenga; Sadeep Shrestha; Maurizio Macaluso; Edward E Partridge; Gary L Johanning; Chandrika J Piyathilake
Journal:  Gynecol Oncol       Date:  2014-10-01       Impact factor: 5.482

5.  Variants in interleukin family of cytokines genes influence clearance of high risk HPV in HIV-1 coinfected African-American adolescents.

Authors:  Staci L Sudenga; Howard W Wiener; Aditi Shendre; Craig M Wilson; Jianming Tang; Sadeep Shrestha
Journal:  Hum Immunol       Date:  2013-08-21       Impact factor: 2.850

Review 6.  A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients.

Authors:  Stefan Miladinov Kovachev
Journal:  Infect Drug Resist       Date:  2021-06-02       Impact factor: 4.003

Review 7.  The East Africa Consortium for human papillomavirus and cervical cancer in women living with HIV/AIDS.

Authors:  Y Tong; E Orang'o; M Nakalembe; P Tonui; P Itsura; K Muthoka; M Titus; S Kiptoo; A Mwangi; J Ong'echa; R Tonui; B Odongo; C Mpamani; B Rosen; A Moormann; S Cu-Uvin; J A Bailey; C I Oduor; A Ermel; C Yiannoutsos; B Musick; E Sang; A Ngeresa; G Banturaki; A Kiragga; J Zhang; Y Song; S Chintala; R Katzenellenbogen; P Loehrer; D R Brown
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

8.  The Potential Clinical and Economic Value of a Human Papillomavirus Primary Screening Test That Additionally Identifies Genotypes 31, 45, 51, and 52 Individually.

Authors:  Lindsey Asti; Colin Hopley; Cameron Avelis; Sarah M Bartsch; Leslie E Mueller; Molly Domino; Sarah N Cox; Jeffrey C Andrews; Samuel L Randall; Owen J Stokes-Cawley; Caitlin Asjes; Bruce Y Lee
Journal:  Sex Transm Dis       Date:  2021-05-01       Impact factor: 2.830

9.  Dense genotyping of immune-related loci identifies variants associated with clearance of HPV among HIV-positive women in the HIV epidemiology research study (HERS).

Authors:  Staci L Sudenga; Howard W Wiener; Caroline C King; Anne M Rompalo; Susan Cu-Uvin; Robert S Klein; Keerti V Shah; Jack D Sobel; Denise J Jamieson; Sadeep Shrestha
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

10.  Prevalence, Genotype Distribution and Risk Factors for Cervical Human Papillomavirus Infection in the Grand Tunis Region, Tunisia.

Authors:  Monia Ardhaoui; Emna Ennaifer; Hajer Letaief; Rejaibi Salsabil; Thalja Lassili; Karim Chahed; Souha Bougatef; Asma Bahrini; Emna El Fehri; Kaouther Ouerhani; Adela Paez Jimenez; Ikram Guizani; Med Samir Boubaker; Nissaf Bouafif Ép Ben Alaya
Journal:  PLoS One       Date:  2016-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.